三价口服脊髓灰质炎疫苗停用后人群脊髓灰质炎病毒免疫力分析
研究建立动态模型估算优先地区国家按血清型和地区级的脊髓灰质炎免疫水平,并分析2016年以来变化。结果显示常规免疫强的地区1型和3型免疫可能提升,但常规免疫薄弱地区预防性补充免疫活动减少未被新程序弥补;2型黏膜免疫普遍下降且mOPV2使用造成高度异质性。
要点
- 常规免疫强地区由tOPV改bOPV后1型和3型人群免疫可能提升
- 常规免疫弱地区预防性SIAs减少未被新程序免疫原性改善补偿
- 2型黏膜免疫几乎普遍下降,mOPV2使用造成高度异质性免疫
核心结论
- 停用tOPV和预防性bOPV补充免疫活动资源分配下降,导致研究地区脆弱人群1型和3型免疫降低、2型免疫普遍降低(假定SIAs覆盖率均一为50%和80%)。
- 2型脊髓灰质炎病毒黏膜免疫极低,大幅增加cVDPV2疫情进一步传播的风险。
- 所有血清型免疫缺口的出现要求全球消灭脊髓灰质炎行动(GPEI)将有限资源审慎投向最脆弱人群。
研究设计与样本
- 建立口服脊髓灰质炎病毒疫苗诱导免疫的动态模型,估算优先地区国家按血清型和地区级的免疫水平。
- 分析2016年以来免疫变化,考虑常规免疫程序变化及预防性和疫情应对补充免疫活动的不同实施情况。
- 模型假定补充免疫活动覆盖率均一为50%和80%。
主要发现
- 常规免疫强的地区,由tOPV改为bOPV可能带来1型和3型脊髓灰质炎病毒人群免疫提升。
- 常规免疫薄弱地区,新程序免疫原性改善未补偿预防性补充免疫活动的减少。
- 2型脊髓灰质炎病毒方面,常规免疫和补充免疫活动中无tOPV后,黏膜免疫几乎在所有地区下降。
- mOPV2使用造成高度异质性人群免疫,应对cVDPV2疫情时需考虑该异质性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global withdrawal of trivalent oral poliovirus vaccine (OPV) (tOPV, containing Sabin poliovirus strains serotypes 1, 2 and 3) from routine immunization, and the introduction of bivalent OPV (bOPV, containing Sabin poliovirus strains serotypes 1 and 3) and trivalent inactivated poliovirus vaccine (IPV) into routine immunization was expected to improve population serologic and mucosal immunity to types 1 and 3 poliovirus, while population mucosal immunity to type 2 poliovirus would decline. However, over the period since tOPV withdrawal, the implementation of preventive bOPV supplementary immunization activities (SIAs) has decreased, while outbreaks of type 2 circulating vaccine derived poliovirus (cVDPV2) have required targeted use of monovalent type 2 OPV (mOPV2). METHODS: We develop a dynamic model of OPV-induced immunity to estimate serotype-specific, district-level immunity for countries in priority regions and characterize changes in immunity since 2016. We account for the changes in routine immunization schedules and varying implementation of preventive and outbreak response SIAs, assuming homogenous coverages of 50% and 80% for SIAs. RESULTS: In areas with strong routine immunization, the switch from tOPV to bOPV has likely resulted in gains in population immunity to types 1 and 3 poliovirus. However, we estimate that improved immunogenicity of new schedules has not compensated for declines in preventive SIAs in areas with weak routine immunization. For type 2 poliovirus, without tOPV in routine immunization or SIAs, mucosal immunity has declined nearly everywhere, while use of mOPV2 has created highly heterogeneous population immunity for which it is important to take into account when responding to cVDPV2 outbreaks. CONCLUSIONS: The withdrawal of tOPV and declining allocations of resources for preventive bOPV SIAs have resulted in reduced immunity in vulnerable areas to types 1 and 3 poliovirus and generally reduced immunity to type 2 poliovirus in the regions studied, assuming homogeneous coverages of 50% and 80% for SIAs. The very low mucosal immunity to type 2 poliovirus generates substantially greater risk for further spread of cVDPV2 outbreaks. Emerging gaps in immunity to all serotypes will require judicious targeting of limited resources to the most vulnerable populations by the Global Polio Eradication Initiative (GPEI).
引用
- Voorman A, Lyons H, Bennette C, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2022. PMID: 35339308. doi:10.1016/j.vaccine.2022.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。